Table 3.

Calibration performance of the CBC risk model

Validation dataset	E/O ratio at 5 years (95% CI)	E/O ratio at 10 years (95% CI)	Calibration slope (95% CI)
Europe—Other	0.87 (076 to 0.98)	0.75 (0.68 to 0.81)	1.11 ( 0.40 to 1.83)
Europe—Scandinavia	1.59 (1.28 to 1.91)	1.23 (1.08 to 1.38)	0.86 ( 0.16 to 1.57)
Europe—UK	1.35 (1.38 to 2.17)	1.82 (1.53 to 2.11)	0.85 (− 0.03 to 1.73)
Netherlands—BOSOM	0.45 (0.37 to 0.53)	0.50 (0.43 to 0.57)	1.34 ( 0.76 to 1.93)
Netherlands—EMC	0.48 (0.38 to 0.57)	0.43 (0.37 to 0.50)	1.19 ( 0.65 to 1.73)
Netherlands—NCR	0.57 (0.54 to 0.59)	0.54 (0.52 to 0.56)	1.40 ( 1.11 to 1.68)
US and Australia	0.43 (0.33 to 0.54)	0.56 (0.45 to 0.67)	1.13 ( 0.25 to 2.00)
Meta-analysis	0.86 (0.50 to 1.46)	0.82 (0.51 to 1.32)	1.26 ( 1.01 to 1.50)
95% PI	0.20 to 3.75	0.21 to 3.14	1.01 to 1.50

Chowdhury et al. [7]

E/O expected-observed, CI confidence interval, UK United Kingdom, BOSOM Breast Cancer Outcome Study of Mutation carriers, EMC Erasmus Medical Center, NCR Netherlands Cancer Registry, PI prediction interval